Moreover, among transfusion-dependent MDS patients, a significant survival advantage has been demonstrated in patients responding to ESAs as compared to those resistant or to subjects never treated with EPO (median 52 months vs. 31 months, p<0.0095).9 This evidence concerns the gene EPO and myelodysplastic syndrome.